PTH plays a central role in regulating turnover of bone and in plasma Ca 2 + (and phosphate) homoeostasis. PTH is released from chief cells in the parathyroid glands when the plasma Ca 2 + concentration decreases and then, via its direct (kidney and bone) or indirect (intestines) actions, it contributes to restoring the plasma Ca 2 + concentration [1] . These responses are mediated by PTHR1 (type 1 PTH receptors), GPCRs (G-protein-coupled receptors) that bind PTH and PTHrP (PTH-related peptide) with similar affinity [2] . The response of bone to PTH depends on interactions between osteoblasts, the cells that deposit bone, and osteoclasts, the cells that mediate bone resorption, because only osteoblasts express PTHR1. Exploitation of PTHR1 as a target for treatment
of osteoporosis seeks selectively to harness the anabolic effects of PTH while minimizing the osteoclast-mediated resorption and associated hypercalcaemia [3] . At present, this relies on pulsatile delivery of PTH, but a clearer understanding of the underlying mechanisms may lead to less intrusive and more effective therapy. Although PTH is best known for its role in plasma Ca 2 + homoeostasis and bone remodelling, consonant with the high levels of expression of PTHR1 in bone and kidney, PTHR1 is also expressed in many diverse tissues, including vascular smooth muscle, hepatocytes, cardiac myocytes and lymphocytes [4] .
Circulating 'PTH' includes the full-length peptide, PTH-(1-84), perhaps some short-lived N-terminal fragments [although not PTH-(1-34), see below], and large amounts of long-lived C-terminal fragments generated before and after secretion. Many of the C-terminal fragments are biologically active, often opposing the effects of PTH-(1-84), but their receptors have not been identified [4] . The biological actions of PTH at PTHR1 are replicated by its N-terminal sequence, PTH- , which is conserved in all vertebrates [1, 4] ( Figure 1a ). PTHR1, like other class II GPCRs, has a long cytosolic N-terminus [2] . The C-terminal α-helical end of PTH-(1-34) binds first to this region (the 'N-domain') and thereby, via a flexible linking loop, positions the α-helical N-terminal of PTH- to bind more slowly to the juxtamembrane region of the receptor ('J-domain') [3, 5] ( Figure 1b ). These interactions with the J-domain lead to receptor activation. (a) Representations of PTH and PTHrP show the essential N-terminal residues of PTH (blue, residues 1-34) and the similar N-terminal structure of PTHrP with perfectly conserved residues shown in blue. (b) PTHR1 is a class II GPCR with a large extracellular N-terminus. The C-terminal region of PTH-(1-34) binds first to this N-terminal region (the N-domain) and then more slowly to the J-domain. PTH analogues appear to differ in their interactions with the two domains. Activation of PTHR1 can lead directly to activation of the G-proteins G s and G q ; residues that uniquely affect coupling to one or other G-protein are highlighted. Phosphorylation of the C-terminal tail of PTHR1 by GRKs allows it to associate with β-arrestins.
Versatile signalling mechanisms of PTHR1
PTHR1 shares with other class II GPCRs an ability to activate several intracellular signalling pathways, including those involving cAMP and Ca 2 + . The importance of cAMP in mediating the effects of PTH is evident from patients with pseudohypoparathyroidism, where a maternal mutation of G s (the only allele expressed in kidney tubules) causes renal PTH-resistance. The immediate consequences of activating PTHR1 differ between cell types, and even between studies of the same cell lines. In some cells, PTH activates AC (adenylate cyclase) without activating PLC (phospholipase C) [6, 7] , in others, it activates PLC and not AC (see references in [8] ), and in further cells still, notably osteoblasts and kidney tubules, it activates both [9] . Even within the same proximal tubule cell, PTH activates PLC from the apical surface and AC from the basolateral surface [10, 11] . Heterologously expressed PTHR1 can also mediate stimulation of both PLC and AC [12] , confirming that a single receptor can elicit both effects. Several factors contribute to whether PTHR1 stimulates AC and/or PLC.
First, expression levels of PTHR1 and of the G-proteins with which it can interact influence the fidelity of G-protein coupling. All levels of expression of PTHR1 allow activation of AC via G s [13] , while high levels allow additional coupling to PLC via G q or G i /G o [14] . Overexpression of G q can also allow PTHR1 that would otherwise stimulate only AC to activate PLC [6, 15, 16] . Intense stimulation [15] or high levels of expression of the signalling proteins can therefore allow PTHR1 to stimulate PLC [17] (Figure 2) .
Secondly, different analogues of PTH cause PTHR1 to adopt different conformations and thereby to interact selectively with different downstream signalling partners, for example, G-proteins and the GRKs (G-protein receptor kinases) that phosphorylate the C-terminal tail of PTHR1 allowing β-arrestins to bind. This phenomenon, where a single receptor responds differently to different ligands, is described as 'stimulus trafficking' [18] (Figure 2 ). It is particularly relevant to PTHR1 because its endogenous ligands, PTH and PTHrP, evoke different physiological responses. Most significant for the treatment of osteoporosis is the observation that both increase bone density, but PTHrP causes less bone resorption and hypercalcaemia than does PTH [3, 19] .
For PTH, residues within its N-and C-termini were suggested to contribute selectively to stimulation of AC and PLC respectively. Although that now seems too simple an interpretation [20] [17, 21] , and point mutations within the first [22] , second [16] or third [23] intracellular loop of PTHR1 selectively affect coupling to AC or PLC ( Figure 1b ). The versatility of PTHR1 signalling is increased further by its coupling to β-arrestin in a receptor conformation described as R 0 (to distinguish it from the conformation that binds to G-proteins) [3] . Ligands, via different interactions with the J-domain of PTHR1, differ in the extent to which they stabilize this R 0 conformation: PTH, for example, is better than PTHrP [5, 19] . The association of PTHR 0 with β-arrestin has at least two important consequences: stimulation of the MAPK (mitogen-activated protein kinase) cascade [21] and trafficking of PTHR1 to early endosomes [5] . β-Arrestin is commonly associated with desensitization of GPCRs (including PTHR1 [24] ), but some PTHR1 ligands that stabilize R 0 [e.g. PTH-(1-34)] cause more long-lasting activation of AC than those that do not [e.g. PTHrP-(1-36)] [5, 19, 25] . Exciting insight into this apparent paradox is provided by recent work showing that AC and G s are internalized with the PTH-PTHR1-β-arrestin complex. Within early endosomes, functional interactions between PTHR1, G s and AC then allow very sustained cAMP production within the cell [5, 25] . Receptors for other peptide hormones behave similarly [26] . Analogues of PTH differ in their abilities to activate G s or promote association of PTHR1 with β-arrestin: Trp 1 PTHrP-(1-36) activates G s without recruiting β-arrestin (and so stimulates AC only at the plasma membrane and fails to activate the MAPK cascade), whereas D-Trp 12 ,Tyr 34 -PTH-(7-34) promotes recruitment of β-arrestin but not activation of G s (and so stimulates MAPK, but not AC) [21] . The latter analogue selectively enhances osteoblast activity without the accompanying recruitment of osteoclasts and ensuing bone resorption [27] . This suggests that it may be an attractive candidate for treatment of osteoporosis with less risk of the hypercalcaemia associated with current daily injections of PTH. These results highlight both the versatility provided by stimulus trafficking and the potential utility of 'biased ligands' as a means of diminishing adverse clinical effects.
A third influence on the coupling of PTHR1 to AC and PLC is provided by scaffold proteins, notably the oligomeric 
NHERF (Na
+ /H + exchanger regulatory factor) proteins. Their association with PTHR1 influences the specificity of coupling to G-proteins and β-arrestins [8] (Figure 2 ). In addition, NHERFs regulate subcellular targeting of PTHR1, its desensitization and internalization, and inhibition of phosphate transport in proximal tubules by PTH [7, 28] .
NHERF1 and NHERF2 are cytosolic proteins each with a MERM (merlin/ezrin/radixin/moesin) domain and two PDZ domains, through which they interact with various proteins, including several GPCRs [29] . The MERM domain, via its interactions with the actin cytoskeleton, allows targeting of PTHR1 to the apical membrane of polarized cells [30] and inhibition of renal phosphate uptake by PTH [7] . Most relevant to the present discussion are the effects of NHERF on the interactions of PTHR1 with G-proteins and β-arrestins (Figure 2 ). Association with NHERF1 allows PTHR1 to stimulate G q and thereby PLC without compromising its ability to stimulate G s and AC [9, 31] . This effect probably accounts for the ability of apical PTHR1 associated with NHERF1 in proximal tubules to activate PLC, whereas basolateral PTHR1 activates only AC [32] . NHERF2 promotes coupling of PTHR1 to G q and G i , while compromising its interaction with G s [8, 9] . NHERF2 can thereby switch PTHR1 from activating AC to activating PLC [8] . Different patterns of expression of NHERF among cells that express PTHR1 undoubtedly contribute to the diversity of signalling pathways activated by PTH [33] . However, the effects of NHERFs may themselves vary between cells: in rat osteosarcoma cells, for example, NHERF1 allows PTHR1 to associate with the cytoskeleton, but it does not facilitate coupling to PLC [34] . NHERF1 also competes with β-arrestin2 for binding to phosphorylated PTHR1, thereby slowing desensitization [24] . This interaction would presumably also uncouple PTHR1 from the MAPK pathway and prevent sustained cAMP signalling from endosomes. Finally, calpain (a Ca 2 + -activated protease) also associates with the C-terminal tail of PTHR1 [35] 
Direct regulation of IP 3 Rs by cAMP at AC-IP 3 R junctions
In HEK (human embryonic kidney)-293 cells stably expressing modest levels of human PTHR1 (∼10 5 receptors/cell), PTH stimulates AC, but not PLC, and neither does it directly increase [Ca 2 + ] i [41] . However, PTH massively potentiates the Ca 2 + signals evoked by either receptors that stimulate PLC, such as the endogenous M 3 muscarinic receptors of HEK-293 cells, or by flash-photolysis of caged Ins(1,4,5)P 3 . In intact cells, these effects of PTH are entirely mimicked by high concentrations of the membrane-permeant analogue of cAMP, 8-Br-cAMP (8-bromo-cAMP); and in permeabilized cells, they are mimicked by cAMP [38, 41] . Indeed, the activity of all three subtypes of mammalian IP 3 Rs is potentiated by cAMP [38] . Considerable evidence suggests that the ability of PTH to potentiate Ins(1,4,5)P 3 -evoked Ca 2 + release is entirely mediated by cAMP [41] . However, the effect does not require activation of PKA and neither is it mimicked by activation of PKA [38, 41] . Furthermore, the effects of 8-Br-cAMP in intact cells are not mimicked by a similarly membrane-permeant analogue of cAMP that selectively activates Epac [41] . These results indicate that high concentrations of cAMP, at least 100-fold higher than required to activate PKA, can sensitize IP 3 R to Ins(1,4,5)P 3 without involvement of the classical targets of cAMP, PKA and Epac. We suggest that a novel low-affinity cAMP-binding site on either the IP 3 R itself or a tightly associated protein allows cAMP to directly increase the efficacy of Ins(1,4,5)P 3 .
Three initially perplexing observations suggest that the delivery of cAMP to IP 3 R in intact cells requires a very specific association of IP 3 R with AC. First, despite evidence that cAMP entirely mediates the effects of PTH, measurements of total cAMP levels in cells suggest that global concentrations of cAMP are unlikely to be sufficient to sensitize IP 3 R [41] . Secondly, all three IP 3 R subtypes are sensitized by Ins(1,4,5)P 3 , yet our use of siRNA (small interfering RNA) selectively to reduce expression of IP 3 R1 and IP 3 R2 (the major subtypes in HEK-293 cells) suggests that potentiation of Ins(1,4,5)P 3 -evoked Ca 2 + release by signals, but with hugely different effects on cAMP. Even substantial inhibition of AC (>80%) has no effect on the ability of any concentration of PTH, maximal or submaximal, to potentiate Ins(1,4,5)P 3 -evoked Ca 2 + signals. These and related observations [41] led us to propose that an intimate association between AC6 and IP 3 R2, an 'AC-IP 3 R junction', allowed cAMP to be delivered directly and at very high local concentration to an associated IP 3 R, maximally sensitizing it to Ins(1,4,5)P 3 ( Figure 3 ). With this scheme, each junction operates as a binary on-off switch, and with a considerable safety margin because the AC delivers more cAMP to each IP 3 R than is required to cause its maximal sensitization. The concentration-dependent effects of PTH, we suggest, then arise not from graded changes in the activity within each junction (they are either on or off), but from graded recruitment of individual junctions: the higher concentrations of PTH allow more junctions to be activated. These results reveal yet another link between PTH and [Ca 2 + ] i that requires costimulation of a receptor linked to activation of PLC. PTH, by stimulating delivery of cAMP within the AC6-IP 3 R2 junction, then potentiates the responses to Ins(1,4,5)P 3 .
Conclusions
PTHR1, as the receptor that mediates the most important biological actions of PTH and as a proven target for treatment of osteoporosis, commands attention, but it also provides a striking illustration of the versatility of the signalling mechanisms emanating from a single GPCR. Stimulus intensity, stimulus trafficking and association with scaffold proteins all contribute to defining the interactions of PTHR1 with intracellular signalling proteins (G-proteins or β-arrestins) (Figure 2) . Furthermore, the cAMP that is usually produced when PTHR1 is activated contributes to generation of intracellular Ca 2 + signals via each of the conventional targets of cAMP, Epac (stimulation of PLCε) and PKA (phosphorylation of Ca 2 + channels), and by interaction with a novel site on the IP 3 R (Figure 3 ). 
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